The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
An Opioid Agonist that Does Not Induce μ-Opioid Receptor—Arrestin Interactions or Receptor Internalization
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, R. H., Laporte, S. A., Holt, J. A., Barak, L. S., & Caron, M. G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101450200 · Cited by 455
Cited by
Molecular mechanisms of opioid receptor-dependent signaling and behavior
Al-Hasani, R., & Bruchas, M. R. (2011) · Anesthesiology · doi:10.1097/aln.0b013e318238bba6 · Cited by 1,067
Structure-based discovery of opioid analgesics with reduced side effects
Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D., Corder, G., Levit, A., Kling, R. C., Bernat, V., Hübner, H., et al. (2016) · Nature · doi:10.1038/nature19112 · Cited by 944
Teaching old receptors new tricks: biasing seven-transmembrane receptors
Rajagopal, S., Rajagopal, K., & Lefkowitz, R. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3024 · Cited by 825
Signalling bias in new drug discovery: detection, quantification and therapeutic impact
Kenakin, T., & Christopoulos, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3954 · Cited by 740
Biased signalling: from simple switches to allosteric microprocessors
Smith, J. S., Lefkowitz, R. J., & Rajagopal, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.229 · Cited by 738
DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647
“…endpoints can be difficult to measure in low-sensitivity assays (Whistler and von Zastrow, 1998; Sternini et al., 2000), which sometimes require overexpressed G protein-coupled receptor kinase to amplify signal (Groer et al., 2007), but is clearly detectable in the more sensitive assays used here.”
Methodβ-Arrestin-biased ligands at seven-transmembrane receptors
Violin, J. D., & Lefkowitz, R. J. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.006 · Cited by 606
A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling
Wisler, J. W., DeWire, S. M., Whalen, E. J., Violin, J. D., Drake, M. T., Ahn, S., Shenoy, S. K., & Lefkowitz, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707936104 · Cited by 597
Mu Opioids and Their Receptors: Evolution of a Concept
Pasternak, G. W., & Pan, Y.-X. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007138 · Cited by 578
Kenakin, T., & Miller, L. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.108.000992 · Cited by 573
Functional Selectivity and Biased Receptor Signaling
Kenakin, T. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.173948 · Cited by 505
Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction
Christie, M. J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.100 · Cited by 478
Agonist‐selective mechanisms of GPCR desensitization
Kelly, E., Bailey, C. P., & Henderson, G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707604 · Cited by 388
Kruegel, A. C., Gassaway, M. M., Kapoor, A., Váradi, A., Majumdar, S., Filizola, M., Javitch, J. A., & Sames, D. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b00360 · Cited by 325
Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment
Comer, S. D., & Cahill, C. M. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.12.005 · Cited by 302
Opioid Analgesia and Opioid-Induced Adverse Effects: A Review
Paul, A. K., Smith, C. M., Rahmatullah, M., Nissapatorn, V., Wilairatana, P., Spetea, M., Gueven, N., & Dietis, N. (2021) · Pharmaceuticals · doi:10.3390/ph14111091 · Cited by 300
Biased agonism: An emerging paradigm in GPCR drug discovery
Rankovic, Z., Brust, T. F., & Bohn, L. M. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.12.024 · Cited by 282
Self-citationRaehal, K. M., Schmid, C. L., Groer, C. E., & Bohn, L. M. (2011) · Pharmacological Reviews · doi:10.1124/pr.111.004598 · Cited by 256
Self-citationClerodane diterpenes: sources, structures, and biological activities
Li, R., Morris-Natschke, S. L., & Lee, K.-H. (2016) · Natural Product Reports · doi:10.1039/c5np00137d · Cited by 256
Raehal, K. M., & Bohn, L. M. (2014) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-41199-1_22 · Cited by 154
“In cell culture studies, these agonists promote both β-arrestin1 and β-arrestin2 interactions with the MOR, whereas morphine weakly and selectively recruits β-arrestin2 (Zhang et al. 2008; Whistler et al 1999; Bohn et al. 2004; Groer et al. 2007; McPherson et al 2010; Molinari et al. 2010).”
BackgroundSelf-citationOptimization of a series of mu opioid receptor (MOR) agonists with high G protein signaling bias
Kennedy, N. M., Schmid, C. L., Ross, N. C., Lovell, K. M., Yue, Z., Chen, Y. T., Cameron, M. D., Bohn, L. M., & Bannister, T. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01136 · Cited by 71
Self-citationThompson, A., Stephens, J. W., Bain, S. C., & Kanamarlapudi, V. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154229 · Cited by 19
“The μ-opioid receptor agonist, herkinorin, induces ERK1/2 phosphorylation but not internalisation of the receptor [40].”
Background
Metadata
- Authors
- Groer, C. E., Tidgewell, K., Moyer, R. A., Harding, W. W., Rothman, R. B., Prisinzano, T. E., & Bohn, L. M.
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 71
- Issue
- 2
- Pages
- 549-557
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W2117762969
- Cited by
- 224
- References
- 1
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.